Elasmogen has isolated soloMERs™ to novel targets and where antibody formats have failed to deliver. In addition, Elasmogen has isolated soloMERs™ to novel epitopes on a broad portfolio of disease targets, delivering increased potency and superior efficacy to current antibody formats.
Their small size and simple protein architecture facilitates flexible reformatting, making them ideal for systemic and site-specific delivery such as topical, implant and gut. These properties also allow superior drug conjugation efficiencies and drug chemistry options.
soloMER™ generation is delivered via our immunisation facilities and/or from our diverse synthetic libraries (in excess of 100 billion clones) with both approaches protected by a portfolio of granted patents in the US, Europe and other geographies.
Unique to Elasmogen, and critical for rapid therapeutic development, we have granted patents that cover soloMER isolation, humanisation, multimerisation, conjugation to biomaterials and half-life extension for enhanced systemic exposure.